Imeik Technology Development Co (300896.SZ) Stock Price

Imeik Technology Development Co Price

SZSE·CLOSED
88.64
​
Market closed

Over the last 11 years Imeik Technology Development Co grew revenue by 37.1% annually, reaching 2.42 B CNY. Earnings per share have grown at 41.5% per year over the last 11 years. For Imeik Technology Development Co, the net margin of 53.3% is down versus 66.2% a few years ago. At today's price the dividend yield works out to roughly 5.64%. The payout ratio is around 117% of earnings. The dividend has grown at 37.7% per year over the past 4 years. The consensus 12-month price target for Imeik Technology Development Co is 186.66 CNY, about 110.6% above where the stock trades today. Of 17 analysts, 14 rate the stock a buy — an overall Buy consensus.

Imeik Technology Development Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imeik Technology Development Co business model & stock analysis

Imeik Technology Development Co., Ltd. generates revenue through the research, development, and industrialization of biomedical materials, particularly recombinant proteins and peptides. The company focuses on products like injection-type sodium hyaluronate series and polydioxanone facial implants, which are used for facial and neck skin repair in medical cosmetology, surgical repair, and metabolic disease treatment. Its self-developed products target the Chinese market, where it has established a technology transformation platform for materials such as medical chitosan and polylactic acid. The firm leverages its industrialized product lines to serve medical and cosmetic applications. The company's primary customers are healthcare providers and medical facilities in China that utilize its products for skin repair, surgical procedures, and metabolic disease management. Its product portfolio includes sodium hyaluronate series for injections, polydioxanone facial implants, and other biomedical materials like medical chitosan and polylactic acid. These products are sold under the company's own brand, with no external brands mentioned in the description. Imeik's business model centers on the industrialization of its self-developed biomedical materials, transforming research into commercial products for medical and cosmetic use. The firm's focus on recombinant proteins and peptides drives its product development, targeting applications in medical cosmetology and surgical repair. It operates within the Chinese market, where it has established a technology platform for product transformation and commercialization.

Frequently asked questions about Imeik Technology Development Co

Analysts currently set an average price target of 197.99 CNY for the Imeik Technology Development Co stock (median: 186.66 CNY), implying +128.1 % versus the latest price. The consensus is based on 17 analyst ratings.

17 analysts currently rate the Imeik Technology Development Co stock: 14 recommend buying, 2 holding and 1 selling. For 2026, analysts expect Imeik Technology Development Co to generate revenue of 2.49 B CNY and earnings per share of 3.87 CNY.

Converted at the current exchange rate, the Imeik Technology Development Co share trades at 11.85 EUR (88.64 CNY).

The Imeik Technology Development Co share (300896.SZ) is listed on 1 stock exchanges, including: Shenzhen (300896.SZ).

The expected revenue of Imeik Technology Development Co is 2.49 B CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Imeik Technology Development Co is 1.17 B CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Imeik Technology Development Co is currently 22.92. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Imeik Technology Development Co stock.

The price-to-sales ratio (P/S) of Imeik Technology Development Co is currently 10.74. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Imeik Technology Development Co stock.

The Eulerpool Quality Score for Imeik Technology Development Co is 8/10.

The ISIN of Imeik Technology Development Co is CNE100004868. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Imeik Technology Development Co is 300896.SZ. The ticker symbol is used to trade Imeik Technology Development Co shares on the stock exchange.

Fair ValueTerminal
74.46 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
3.40 M CNY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website imeik.net
Country
Currency
CNY
Initial public offering
Sep 28, 2020
ISIN
CNE100004868
Cusip
Y385KL109
Market capitalization
26.70 B CNYLarge Cap
52-Week Range
PEG
0.53
P/E ratio
P/Ee 2026
22.90
P/Ee 2027
20.79
P/Ee 2028
18.79
P/Ee 2029
6.08
P/Se
10.74
EV/EBIT
20.29
P/B Ratio
3.52
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
17.02 %
Dividend
Dividend yield
5.64 %
Est. Dividend Yield
1.81 %
Payout Ratio
116.74 %
Dividend growth Ø5Y
—
Dividend payments per year
2
Dividend paid since
5 years
Dividend not reduced since
1 year
Dividend increased since
1 year
Dividend withholding tax
10.00 %
Last updated Nov 11, 2026, 2:45 PM

Imeik Technology Development Co Peer Group

Imeik Technology Development Co Ticker

SHZ · 300896.SZ

Imeik Technology Development Co FIGI

300896:CH · BBG00H40V3P9300896:CS · BBG00H40V3R7300896:C2 · BBG011C97SS4